Mad River Investors Buys Shares of 1,200 Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on May 3rd, 2023

Mad River Investors bought a new stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,200 shares of the company’s stock, valued at approximately $212,000. Johnson & Johnson makes up approximately 0.1% of Mad River Investors’ holdings, making the stock its 22nd largest holding.

Several other institutional investors also recently bought and sold shares of JNJ. Nordwand Advisors LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $785,273,000. Edmp Inc. increased its stake in shares of Johnson & Johnson by 17,222.9% in the fourth quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock worth $18,247,000 after purchasing an additional 3,204,658 shares during the period. Vanguard Group Inc. increased its stake in shares of Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after purchasing an additional 2,815,655 shares during the period. GQG Partners LLC increased its stake in shares of Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of Johnson & Johnson by 37.2% in the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after purchasing an additional 1,805,632 shares during the period. 67.94% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Guggenheim assumed coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective on the stock. UBS Group assumed coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. SVB Leerink decreased their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Finally, Atlantic Securities reduced their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday, April 19th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $173.00.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $165.03 on Wednesday. The firm has a fifty day moving average of $158.00 and a two-hundred day moving average of $167.05. The stock has a market capitalization of $429.79 billion, a price-to-earnings ratio of 34.53, a PEG ratio of 2.78 and a beta of 0.53. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $183.35. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating the consensus estimate of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.67 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a $1.19 dividend. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.88%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is currently 94.56%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.